Chemoradiotherapy in head and neck squamous cell carcinoma: Focus on targeted therapies;La chimioradiothérapie des carcinomes épidermoïdes des voies aérodigestives supérieures : point sur les thérapeutiques ciblées

Cancer/Radiotherapie

Volumn 12, Issue 1, 2008, Pages 14-24

  Bozec, A ^a   Thariat, J ^a   Bensadoun, R J ^a   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

EGFR; Head and neck cancer; Radiotherapy; Targeted therapies

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CEDIRANIB; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; LAPATINIB; MONOCLONAL ANTIBODY; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VANDETANIB;

ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CYTOTOXICITY; HEAD AND NECK CARCINOMA; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 39949084155     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2007.11.003     Document Type: Short Survey

References (97)

1. Abdollahi A., Lipson K.E., Han X., Krempien R., Trinh T., Weber K.J., et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63 (2003) 3755-3763
2. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37 Suppl. 4 (2001) S16-S22
3. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 19 (2001) 41S-44S
4. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 312 (2006) 1175-1178
5. Baselga J., and Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 Suppl. 1 (2001) S35-S41
6. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
7. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
8. Baselga J., Trigo J.M., Bourhis J., Tortochaux J., Cortés-Funes H., Hitt R., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5568-5577
9. Bernard-Marty C., Lebrun F., Awada A., and Piccart M.J. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 66 (2006) 1577-1591
10. Bianco C., Bianco R., Tortora G., Damiano V., Guerrieri P., Montemaggi P., et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6 (2000) 4343-4350
11. Bianco C., Tortora G., Bianco R., Caputo R., Veneziani B.M., Caputo R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8 (2002) 3250-3258
12. Bleeker W.K., Lammerts van Bueren J.J., van Ojik H.H., Gerritsen A.F., Pluyter M., Houtkamp M., et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173 (2004) 4699-4707
13. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
14. Bonner J.A., Raisch K.P., Trummell H.Q., Robert F., Meredith R.F., Spencer S.A., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18 (2000) 47S-53S
15. Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs 12 (2003) 1395-1401
16. Bourhis J., Rivera F., Mesia R., Awada A., Geoffrois L., Borel C., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24 (2006) 2866-2872
17. Bozec A., Formento P., Ciccolini J., Fanciullino R., Padovani L., Murraciole X., et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 4 (2005) 1962-1971
18. Bozec A, Formento P, Lassalle S, Lippens C, Fischel JL, Hofman P, et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour synergistic effects on human head and neck cancer xenografts. Br J Cancer 2007;97(1):65-72.
19. Bozec A., Lassalle S., Gugenheim J., Fischel J.L., Formento P., Hofman P., et al. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 95 (2006) 722-728
20. Bruns C.J., Harbison M.T., Davis D.W., Portera C.A., Tsan R., McConkey D.J., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6 (2000) 1936-1948
21. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
22. Cao C., Albert J.M., Geng L., Ivy P.S., Sandler A., Johnson D.H., et al. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 66 (2006) 11409-11415
23. Caponigro F., Formato R., Caraglia M., Normanno N., and Iaffaioli R.V. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 17 (2005) 212-217
24. Carter S.K. Clinical strategy for the development of angiogenesis inhibitors. Oncologist 5 Suppl. 1 (2000) 51-54
25. Ciardiello F., Bianco R., Damiano V., Fontanini G., Caputo R., Pomatico G., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6 (2000) 3739-3747
26. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6 (2000) 2053-2063
27. Ciardiello F., and Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7 (2001) 2958-2970
28. Cohen E.E., Rosen F., Stadler W.M., Recant W., Stenson K., Huo D., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
29. Cohen S., Carpenter G., and King Jr. L. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255 (1980) 4834-4842
30. Collins T.S., and Hurwitz H.I. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 32 (2005) 61-68
31. Cooney M.M., Tserng K.Y., Makar V., McPeak R.J., Ingalls S.T., Dowlati A., et al. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol 55 (2005) 295-300
32. Dittmann K., Mayer C., Fehrenbacher B., Schaller M., Raju U., Milas L., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280 (2005) 31182-31189
33. Fan Z., Lu Y., Wu X., and Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269 (1994) 27595-27602
34. Fan Z., Shang B.Y., Lu Y., Chou J.L., and Mendelsohn J. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 3 (1997) 1943-1948
35. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
36. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
37. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
38. Gaya A.M., and Rustin G.J. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 17 (2005) 277-290
39. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., and Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (1995) 1311-1318
40. Grandis J.R., and Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53 (1993) 3579-3584
41. Gustafson D.L., Frederick B., Merz A.L., and Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima((R))) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol (2007)
42. Hagan M., Yacoub A., and Dent P. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin Cancer Res 10 (2004) 5724-5731
43. Hainsworth J.D., Sosman J.A., Spigel D.R., Edwards D.L., Baughman C., and Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23 (2005) 7889-7896
44. Herbst R.S. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 30 (2003) 34-46
45. Herbst R.S., Arquette M., Shin D.M., Dicke K., Vokes E.E., Azarnia N., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5578-5587
46. Herbst R.S., Kim E.S., and Harari P.M. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 1 (2001) 719-732
47. Heymach J.V. ZD6474-clinical experience to date. Br J Cancer 92 Suppl. 1 (2005) S14-S20
48. Heymach J.V., Nilsson M., Blumenschein G., Papadimitrakopoulou V., and Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12 (2006) 4441s-4445s
49. Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62 (2002) 2554-2560
50. Hoang T., Huang S., Armstrong E., Eickhoff J.C., and Harari P.M. Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 64 (2006) 1458-1465
51. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
52. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
53. Huang S.M., Li J., Armstrong E.A., and Harari P.M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62 (2002) 4300-4306
54. Johnston S.R., and Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc) 42 (2006) 441-453
55. Jung Y.D., Mansfield P.F., Akagi M., Takeda A., Liu W., Bucana C.D., et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38 (2002) 1133-1140
56. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 (2002) 727-739
57. Kiyota A., Shintani S., Mihara M., Nakahara Y., Ueyama Y., Matsumura T., et al. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology 63 (2002) 92-98
58. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., and Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61 (2001) 39-44
59. Lund E.L., Bastholm L., and Kristjansen P.E. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6 (2000) 971-978
60. Magne N., Fischel J.L., Dubreuil A., Formento P., Marcie S., Lagrange J.L., et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86 (2002) 819-827
61. Magne N., Fischel J.L., Dubreuil A., Formento P., Poupon M.F., Laurent-Puig P., et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 86 (2002) 1518-1523
62. Matsumori Y., Yano S., Goto H., Nakataki E., Wedge S.R., Ryan A.J., et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 16 (2006) 15-26
63. Mauer AM, Cohen EE, Wong SJ, Kozloff M, Winegarden J, Gustin DM, et al. Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). In: Proc Am Assoc Clin Oncol 2004, Abst 5539.
64. McCarty M.F., Wey J., Stoeltzing O., Liu W., Fan F., Bucana C., et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 3 (2004) 1041-1048
65. Milano G. [Pharmacological skills for targeting EGFR and VEGF]. Bull Cancer 92 (2005) S17-S20 (Spec no)
66. Modi S., and Seidman A.D. An update on epidermal growth factor receptor inhibitors. Curr Oncol Rep 4 (2002) 47-55
67. Nelson M.H., and Dolder C.R. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40 (2006) 261-269
68. Nieder C., Wiedenmann N., Andratschke N., and Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 32 (2006) 348-364
69. Ning S., Laird D., Cherrington J.M., and Knox S.J. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157 (2002) 45-51
70. Penault-Llorca F., Bibeau F., Arnould L., Bralet M.P., Rochaix P., and Sabourin J.C. [EGFR expression in colorectal cancer and role in tumorigenesis]. Bull Cancer 92 (2005) S5-S11 (Spec no)
71. Pfister D.G., Su Y.B., Kraus D.H., Wolden S.L., Lis E., Aliff T.B., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24 (2006) 1072-1078
72. Pignon J.P., Baujat B., and Bourhis J. Apport des méta-analyses surdonnées individuelles au traitement des cancers ORL. Cancer Radiother 9 (2005) 31-36
73. Poissonnet G, Benezery K, Peyrade F, Bozec A, Bensadoun RJ, Marcy PY, et al. Cancers ORL: les grands principes therapeutiques. Presse Med 2007;11(2):1634-1642.
74. Prewett M., Rockwell P., Rockwell R.F., Giorgio N.A., Mendelsohn J., Scher H.I., et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19 (1996) 419-427
75. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., and Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8 (2002) 994-1003
76. Raben D., Bianco C., Damiano V., Bianco R., Melisi D., Mignogna C., et al. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther 3 (2004) 977-983
77. Raben D., and Helfrich B. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?. Clin Lung Cancer 6 (2004) 48-57
78. Ranson M., Hammond L.A., Ferry D., Kris M., Tullo A., Murray P.I., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20 (2002) 2240-2250
79. Ryan A.J., and Wedge S.R. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92 Suppl. 1 (2005) S6-S13
80. Sano D., Kawakami M., Fujita K., Kimura M., Yamashita Y., Ishiguro Y., et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 17 (2007) 289-295
81. Schmidt-Ullrich R.K., Contessa J.N., Lammering G., Amorino G., and Lin P.S. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22 (2003) 5855-5865
82. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., Todd D.G., Valerie K., Kavanagh B.D., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
83. Schmidt-Ullrich R.K., Valerie K., Fogleman P.B., and Walters J. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145 (1996) 81-85
84. Schuuring J., Bussink J., Bernsen H.J., Peeters W., and van Der Kogel A.J. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 61 (2005) 529-534
85. Siemann D.W., Bibby M.C., Dark G.G., Dicker A.P., Eskens F.A., Horsman M.R., et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11 (2005) 416-420
86. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
87. Siemann D.W., and Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53 (2002) 164-171
88. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., and Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
89. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10 (2004) 415-427
90. Tortora G., Caputo R., Damiano V., Fontanini G., Melisi D., Veneziani B.M., et al. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res 7 (2001) 4156-4163
91. Vokes EE, Cohen EE, Mauer AM, Karrison TG, Wong SJ, Skoog-Sluman LJ, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). In: Proc Am Assoc Clin Oncol; Abst 5504, 2005.
92. Wachsberger P., Burd R., and Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9 (2003) 1957-1971
93. Wachsberger P., Burd R., and Dicker A.P. Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am 18 (2004) 1039-1057 viii
94. Wachsberger P.R., Burd R., Marero N., Daskalakis C., Ryan A., McCue P., et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11 (2005) 835-842
95. Williams K.J., Telfer B.A., Stratford I.J., and Wedge S.R. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86 (2002) 1157-1161
96. Wirth L.J., Haddad R.I., Lindeman N.I., Zhao X., Lee J.C., Joshi V.A., et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 6976-6981
97. Thariat J., Milas L., and Ang K.K. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 69 4 (2007) 974-984